This paper is only available as a PDF. To read, Please Download here.
Abstract
Because some patients may prefer aqueous nasal sprays and once-daily dosing for relief
of seasonal allergic rhinitis symptoms, a new aqueous formulation of triamcinolone
acetonide (TAA Aqueous) was developed. We conducted a randomized, placebo-controlled,
double-blind study to compare the efficacy and safety of once-daily administration
of 220 μg/d of TAA Aqueous for 1 week, followed by either 220 μg/d or 110 μg/d for
an additional 2 weeks, with that of placebo in 429 patients with seasonal allergic
rhinitis. Patients recorded the severity of symptoms (nasal stuffiness, discharge,
sneezing, nasal index [the sum of the first three variables], nasal itching, and eye
symptoms) on daily diary cards. Patients' and physicians' global evaluations of efficacy
were made at the end of the 3-week study period. Both regimens of TAA Aqueous significantly
improved symptoms compared with placebo at most time points. Patients demonstrated
significant improvements in nasal symptoms as early as the first day of treatment
(within 12 to 16 hours based on treatment in the morning and symptom assessment at
bedtime). Although TAA Aqueous 220 μg/d provided numerically greater reductions in
nasal symptoms compared with 110 μg/d, these differences in efficacy over the last
2 weeks were not statistically significant. The incidence of adverse effects with
both TAA Aqueous regimens was low and comparable to that of placebo. In summary, during
the first week of therapy, TAA Aqueous 220 μg/d significantly reduced nasal symptoms.
During the last 2 weeks of therapy, the 110 μg/d regimen of TAA Aqueous was effective
as continued therapy for most patients. Both the 110 μg/d and 220 μg/d regimens of
TAA Aqueous provided significantly better relief of nasal symptoms than did placebo.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Allergic rhinitis.JAMA. 1988; 259: 260-263
- Allergic rhinitis.NEJM. 1991; 325: 860-869
- Effect of topical corticosteroids on the recovery of histamine releasing factors in nasal washings of patients with allergic rhinitis. A double-blind, randomized, placebo-controlled study.Am Rev Respir Dis. 1992; 145: 1316-1320
- Corticosteroids in the management of upper respiratory allergy: The emerging role of steroid nasal sprays.Otolaryngol Head Neck Surg. 1992; 107: 855-860
- Prevention of pollen rhinitis symptoms: Comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray.Allergy. 1993; 48: 327-333
- Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis.Ann Allergy. 1991; 67: 332-338
- Strategies for enhancing patient compliance.J Community Health. 1980; 6: 113-135
- How often is medication taken as prescribed? A novel assessment technique.JAMA. 1989; 261: 3273-3277
- Efficacy of once-a-day intranasal administration of triamcinolone acetonide in patients with seasonal allergic rhinitis.Ann Allergy. 1992; 68: 228-232
- Multicenter, double-blind, placebo-controlled trial of triamcinolone acetonide nasal aerosol in the treatment of perennial allergic rhinitis.Ann Allergy. 1990; 64: 300-305
- Once daily triamcinolone acetonide nasal spray is effective for the treatment of perennial allergic rhinitis.Ann Allergy. 1991; 66: 329-334
- Long-term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis.Clin Ther. 1994; 16: 253-262
Data on file, Rhône-Poulenc Rorer Pharmaceuticals Inc., Collegeville, Pennsylvania, 1994.
- Topical intranasal corticosteroid therapy in rhinitis.J Allergy Clin Immunol. 1988; 81: 984-991
- A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis.Allergy. 1992; 47: 313-317
- Intranasal treatment of perennial allergic rhinitis. Comparison of azelastine nasal spray and budesonide nasal aerosol.Arzneim-Forsch Drug Res. 1993; 43: 475-479
- Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis.Clin Otolaryngol Allied Sci. 1991; 16: 527-531
- Triamcinolone acetonide nasal inhaler vs loratadine tablets in patients with seasonal ragweed allergic rhinitis.Ann Allergy Asthma Immunol. 1995; 74 (Abstract): 59
- Aqueous beclomethasone dipropionate nasal spray: Regular versus “as required” use in the treatment of seasonal allergic rhinitis.J Allergy Clin Immunol. 1990; 86: 380-386
- Comparison of the efficacy and side effects of aqueous steroid nasal spray (budelonide) and allergen-injection therapy (Polinex-R) in the treatment of seasonal allergic rhinoconjunctivitis.J Allergy Clin Immunol. 1990; 85: 606-611
- Aqueous beclomethasone dipropionate nasal spray in the treatment of seasonal (ragweed) rhinitis.Can Med Assoc J. 1992; 147: 887-892
- J R Coll Gen Pract. 1968; 16 (To be taken as directed): 39-44
Article info
Identification
Copyright
© 1995 Published by Elsevier Inc.
